Exbio — Research products — Antibodies — Serum, plasma, and secreted proteins — Anti-Hu C3d APC

Anti-Hu C3d APC

Regulatory status

RUO

Antigen

C3d

Clone

BGRL11

Format

APC

Reactivity

Human

Application

FC (QC tested)

Excitation laser

red (633 nm)

Variant

100 tests

1A-955-T100

In stock

248.60 USD

Variant

100 tests

1A-955-T100

In stock

248.60 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgM

Specificity

The mouse monoclonal antibody BGRL11 recognizes human complement fragment C3d.

Workshop

Human red blood cell workshop in Lund, 1990

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Reactivity

Human

Immunogen

intact human erythrocytes coated with C3/C4

Preparation

Purified antibody is conjugated with activated allophycocyanin (APC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing Tris buffered saline (TBS), pH 8.0, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

complement component C3d

Antigen description

Complement component C3 plays a key role in the activation of complement system. In classical complement system pathway the activated C2 and C4 form classical C3-convertase (C4b2b) which cleaves C3 into C3a and C3b. In alternative complement system pathway C3 is cleaved by alternative C3-convertase (C3bBb), composed of C3b (which can be generated also by spontaneous hydrolysis of C3) and the activated form of factor B. C3b activates downstream cascade leading to formation of pores in the plasma membrane of attacked cell. C3b and its proteolytically inactive form iC3b also serve as important opsonins. C3b can generate C3f, as well as the iC3b can be further cleaved into C3c, C3d and C3g. Complement system is regulated by effective inactivation of free C3b by factor H and factor I. C3b attached to the surface of its target is protected from this inactivation. Complement system is also regulated by other proteins, e.g. CD35, CD46, CD55, or CD59. Undesired activation of complement cascade can lead to severe diseases such as PNH, rheumatoid arthritis, macular degeneration and other. Recently it has been demonstrated to take part in complications associated with Covid-19.

Entrez Gene ID 718

UniProt ID P01024

Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human C3d (BGRL11) APC antibody (concentration in sample 0.56 μg/ml).

Flow cytometry multicolor surface staining pattern of human lymphocytes stained using anti-human CD19 (LT19) PE antibody (20 μl reagent / 100 μl of peripheral whole blood) and anti-human C3d (BGRL11) APC antibody (concentration in sample 0.56 μg/ml).

Separation of human CD19 positive C3d positive B cells (red-filled) from CD19 negative C3d negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human C3d (BGRL11) APC antibody (concentration in sample 0.56 μg/ml).

Product specific references:

Dobbie D, Brazier DM, Gardner B, Holburn AM: Epitope specificities and quantitative and serologic aspects of monoclonal complement (C3c and C3d) antibodies. Transfusion 1987 Nov-Dec;27(6):453-9.
PubMed

Gankema AA, Furumaya C, Fernández-Hermira S, Hoogenboezem M, Matlung HL, van Bruggen R, Kuijpers TW: Efficient complement-mediated clearance of immunosuppressed T cells by macrophages. Front Immunol. 2023 May 16:14:1183180.
PubMed

Smith CJ, Ross N, Kamal A, Kim KY, Kropf E, Deschatelets P, Francois C, Quinn WJ, Singh I, Majowicz A, Mingozzi F, Kuranda K: Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood. Front Immunol. 2022 Sep 16:13:999021.
PubMed